Literature DB >> 2978374

An in-vitro model for tumor immunotherapy with antibody heteroconjugates.

G Jung, H J Eberhard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2978374     DOI： 10.1016/0167-5699(88)91304-7

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


× No keyword cloud information.
  10 in total

1.  Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.

Authors:  L B DeMonte; P Nistico; R Tecce; P Dellabona; M Momo; A Anichini; M Mariani; P G Natali; F Malavasi
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

Review 2.  Lymphokine activated killer cells.

Authors:  A Lindemann; F Herrmann; W Oster; R Mertelsmann
Journal:  Blut       Date:  1989-10

3.  Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.

Authors:  Michael Durben; Dominik Schmiedel; Martin Hofmann; Fabian Vogt; Tina Nübling; Elwira Pyz; Hans-Jörg Bühring; Hans-Georg Rammensee; Helmut R Salih; Ludger Große-Hovest; Gundram Jung
Journal:  Mol Ther       Date:  2015-01-12       Impact factor: 11.454

4.  Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.

Authors:  M Dohlsten; G Hedlund; E Akerblom; P A Lando; T Kalland
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

5.  Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.

Authors:  P Nisticò; R Mortarini; L B De Monte; A Mazzocchi; M Mariani; F Malavasi; G Parmiani; P G Natali; A Anichini
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).

Authors:  I A Haagen; R van de Griend; M Clark; A Geerars; B Bast; B de Gast
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

7.  Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.

Authors:  P F Mansfield; M G Rosenblum; J L Murray; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 x anti-CD16) antibodies.

Authors:  A M Malygin; K Somersalo; T Timonen
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

9.  Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells.

Authors:  G Hedlund; M Dohlsten; C Petersson; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies.

Authors:  Joseph Kauer; Fabian Vogt; Ilona Hagelstein; Sebastian Hörner; Melanie Märklin; Stefanie Maurer; Helmut R Salih; Gundram Jung; Latifa Zekri
Journal:  Cancers (Basel)       Date:  2021-09-13       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.